(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Vera Therapeutics's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast VERA's revenue for 2026 to be $2,265,382,999, with the lowest VERA revenue forecast at $847,464,820, and the highest VERA revenue forecast at $5,569,703,099. On average, 13 Wall Street analysts forecast VERA's revenue for 2027 to be $18,600,267,397, with the lowest VERA revenue forecast at $8,686,514,401, and the highest VERA revenue forecast at $34,997,558,643.
In 2028, VERA is forecast to generate $50,369,388,632 in revenue, with the lowest revenue forecast at $33,830,132,616 and the highest revenue forecast at $93,898,525,505.